A Randomized Open-labeled Study for Comparing Methods of Using Imrecoxib to Treat AS

You may not qualify if:

• complicated with other rheumatic diseases, such as inflammatory bowel disease, psoriasis, active uveitis, rheumatoid arthritis, systemic lupus erythematosus, primary Sjogren's syndrome, systemic vasculitis, etc.
• the anti-infection treatment due to the active periods of acute and chronic infections such as mycobacterium tuberculosis, hepatitis B, hepatitis C, HIV, etc.
• complicated with the malignant tumor.
• complicated with the drug allergies (including sulfonamides, NSAIDs, etc.), allergic diseases or allergies.
• Pregnant or lactating women.
• Abnormal blood system: hemoglobin \<80g / L, white blood cells \<4.0 × 109 / L, platelet \< 100 × 109 / L.
• Insufficient liver and kidney function: 1.5 times higher than the upper limit of normal value of ALT and AST; 1.25 times higher than the upper limit of normal value of creatinine and urea nitrogen.
• Insufficient heart function: New York's heart association (NYHA) level ≥ grade II.
• The usage of analgesic drugs (such as methadone, morphine, etc.) within 4 weeks before baseline.
• Patients received the spine or joint surgery within 2 months before of the enrollment.
• Patients participated the any other clinical trials within 3 months before of the enrollment.
• Patients received live vaccination within 3 months before the enrollment.
• Patients refused to sign the informed consent form, or the patient lack the capacity to decide for themselves.
• Elimination criteria:
• Violation of the diagnostic criteria for AS.
• +10 more criteria